Serum soluble ST2 as a marker of renal scar in pediatric upper urinary tract infection.


Journal

Cytokine
ISSN: 1096-0023
Titre abrégé: Cytokine
Pays: England
ID NLM: 9005353

Informations de publication

Date de publication:
08 2019
Historique:
received: 20 02 2019
revised: 25 04 2019
accepted: 08 05 2019
pubmed: 4 6 2019
medline: 19 8 2020
entrez: 2 6 2019
Statut: ppublish

Résumé

Upper urinary tract infection is the most common serious bacterial infection in childhood. Patients with upper urinary tract infection have a risk for renal scarring with subsequent complications including hypertension, proteinuria, and progressive renal failure. However, the predictive biomarkers of renal scarring in children with upper urinary tract infection are still unknown. In this study, we evaluated whether soluble ST2 levels can be biomarkers of subsequent renal scarring in patients with upper urinary tract infection. We retrospectively studied pediatric patients with upper urinary tract infection at a tertiary center. Twenty-eight children had an upper urinary tract infection with (n = 14) and without (n = 14) renal scarring and underwent 99mtechnetium dimercaptosuccinic acid imaging. In addition, 13 control subjects were enrolled. The clinical data and serum cytokine levels, including soluble ST2 levels, were compared between those with and without renal scars. Serum soluble ST2 levels were significantly higher in the scar group than in the non-scar group, whereas there was no difference in the levels of serum interferon-γ, interleukin-6, interleukin-10, soluble tumor necrosis factor receptor 1, and transforming growth factor-β between the scar and non-scar groups. The area under the curve for differentiating between the non-scar and scar groups on the basis of measurements of serum soluble ST2 was 0.79, with a sensitivity and specificity of 92.9% and 64.3%, respectively. These results suggest that serum soluble ST2 levels on admission could be a useful biomarker of subsequent renal scarring in pediatric patients with upper urinary tract infection.

Sections du résumé

BACKGROUND AND OBJECTIVES
Upper urinary tract infection is the most common serious bacterial infection in childhood. Patients with upper urinary tract infection have a risk for renal scarring with subsequent complications including hypertension, proteinuria, and progressive renal failure. However, the predictive biomarkers of renal scarring in children with upper urinary tract infection are still unknown. In this study, we evaluated whether soluble ST2 levels can be biomarkers of subsequent renal scarring in patients with upper urinary tract infection.
DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS
We retrospectively studied pediatric patients with upper urinary tract infection at a tertiary center. Twenty-eight children had an upper urinary tract infection with (n = 14) and without (n = 14) renal scarring and underwent 99mtechnetium dimercaptosuccinic acid imaging. In addition, 13 control subjects were enrolled. The clinical data and serum cytokine levels, including soluble ST2 levels, were compared between those with and without renal scars.
RESULTS
Serum soluble ST2 levels were significantly higher in the scar group than in the non-scar group, whereas there was no difference in the levels of serum interferon-γ, interleukin-6, interleukin-10, soluble tumor necrosis factor receptor 1, and transforming growth factor-β between the scar and non-scar groups. The area under the curve for differentiating between the non-scar and scar groups on the basis of measurements of serum soluble ST2 was 0.79, with a sensitivity and specificity of 92.9% and 64.3%, respectively.
CONCLUSION
These results suggest that serum soluble ST2 levels on admission could be a useful biomarker of subsequent renal scarring in pediatric patients with upper urinary tract infection.

Identifiants

pubmed: 31153005
pii: S1043-4666(19)30124-3
doi: 10.1016/j.cyto.2019.05.006
pii:
doi:

Substances chimiques

Biomarkers 0
Cytokines 0
IL1RL1 protein, human 0
Interleukin-1 Receptor-Like 1 Protein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

258-263

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Naoki Ohta (N)

Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, Japan. Electronic address: naoki@yamaguchi-u.ac.jp.

Hiroki Yasudo (H)

Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, Japan. Electronic address: yasudo@yamaguchi-u.ac.jp.

Makoto Mizutani (M)

Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, Japan. Electronic address: mizutani@yamaguchi-u.ac.jp.

Takeshi Matsushige (T)

Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, Japan. Electronic address: matsu@yamaguchi-u.ac.jp.

Reiji Fukano (R)

Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, Japan. Electronic address: fukano.r@yamaguchi-u.ac.jp.

Setsuaki Kittaka (S)

Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, Japan.

Kenji Maehara (K)

Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, Japan. Electronic address: maeharak@yamaguchi-u.ac.jp.

Kiyoshi Ichihara (K)

Department of Clinical Laboratory Science, Faculty of Health Science, Yamaguchi University Graduate School of Medicine, Ube, Japan. Electronic address: ichihara@yamaguchi-u.ac.jp.

Shouichi Ohga (S)

Department of Pediatrics, Kyushu University Graduate School of Medical Science, Fukuoka, Japan. Electronic address: ohgas@pediatr.med.kyushu-u.ac.jp.

Shunji Hasegawa (S)

Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, Japan. Electronic address: shunji@yamaguchi-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH